Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details) - USD ($) $ in Thousands	1 Months Ended			12 Months Ended
	Dec. 31, 2025	Mar. 31, 2025	Jun. 30, 2024	Dec. 31, 2025	Dec. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue				$ 102,484	$ 62,043
Vaxcyte Agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue				600	2,576
Vaxcyte Agreements \| Research and Development Services
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue				581	2,287
Vaxcyte Agreements \| Materials Supply
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue				19	289
Ipsen Pharma SAS
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue				56,357	559
Ipsen Pharma SAS \| Ongoing Performance Related to Unsatisfied Performance Obligations
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue				50,429
Ipsen Pharma SAS \| Research and Development Services
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue				71	174
Ipsen Pharma SAS \| Materials Supply
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue				5,857	385
Collaboration and License Agreements and Supply Agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue				102,484	62,043
Collaboration and License Agreements and Supply Agreements \| Merck Sharp & Dohme Corporation ("Merck")
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue					19
Collaboration and License Agreements and Supply Agreements \| Astellas Pharma Inc. ("Astellas")
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue				45,423	52,868
Collaboration and License Agreements and Supply Agreements \| Tasly Biopharmaceuticals Co., Ltd. ("Tasly")
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue				104	6,021
Collaboration and License Agreements and Supply Agreements \| Vaxcyte, Inc.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue				600	2,576
Collaboration and License Agreements and Supply Agreements \| Ipsen Pharma SAS
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue				56,357	559
Astellas License and Collaboration Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue				45,423	52,868
Astellas License and Collaboration Agreement \| Ongoing Performance Related to Unsatisfied Performance Obligations
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue	$ 6,600	$ 5,700	$ 17,800	31,890	39,900
Astellas License and Collaboration Agreement \| Research and Development Services
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue				2,459	5,200
Astellas License and Collaboration Agreement \| Financing Component on Unearned Revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue				3,413	6,289
Astellas License and Collaboration Agreement \| Materials Supply
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue				7,661	1,479
Tasly License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue				104	6,021
Tasly License Agreement \| Contingent Payment
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue				0	5,000
Tasly License Agreement \| Research and Development Services
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue				0	70
Tasly License Agreement \| Materials Supply
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue				$ 104	$ 951